Genmab A/S (LON:0MGB)

Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of GBP 14.87 billion. The enterprise value is 12.43 billion.

Market Cap	14.87B
Enterprise Value	12.43B

Important Dates

The next estimated earnings date is Thursday, February 5, 2026.

Earnings Date	Feb 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	61.60M
Shares Outstanding	n/a
Shares Change (YoY)	-3.12%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	1.15%
Owned by Institutions (%)	53.71%
Float	60.88M

Valuation Ratios

The trailing PE ratio is 12.62 and the forward PE ratio is 21.28.

PE Ratio	12.62
Forward PE	21.28
PS Ratio	5.20
PB Ratio	3.47
P/TBV Ratio	5.48
P/FCF Ratio	15.04
P/OCF Ratio	14.60
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.17, with an EV/FCF ratio of 12.57.

EV / Earnings	10.55
EV / Sales	4.33
EV / EBITDA	11.17
EV / EBIT	11.74
EV / FCF	12.57

Financial Position

The company has a current ratio of 6.03, with a Debt / Equity ratio of 0.02.

Current Ratio	6.03
Quick Ratio	6.01
Debt / Equity	0.02
Debt / EBITDA	0.10
Debt / FCF	0.11
Interest Coverage	54.85

Financial Efficiency

Return on equity (ROE) is 29.41% and return on invested capital (ROIC) is 16.02%.

Return on Equity (ROE)	29.41%
Return on Assets (ROA)	13.38%
Return on Invested Capital (ROIC)	16.02%
Return on Capital Employed (ROCE)	22.58%
Revenue Per Employee	1.07M
Profits Per Employee	439,335
Employee Count	2,682
Asset Turnover	0.58
Inventory Turnover	17.23

Taxes

In the past 12 months, Genmab has paid 146.09 million in taxes.

Income Tax	146.09M
Effective Tax Rate	11.03%

Stock Price Statistics

The stock price has increased by +36.40% in the last 52 weeks. The beta is 0.79, so Genmab's price volatility has been lower than the market average.

Beta (5Y)	0.79
52-Week Price Change	+36.40%
50-Day Moving Average	1,973.00
200-Day Moving Average	1,606.34
Relative Strength Index (RSI)	57.79
Average Volume (20 Days)	40,883

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of GBP 2.86 billion and earned 1.18 billion in profits. Earnings per share was 18.67.

Revenue	2.86B
Gross Profit	2.70B
Operating Income	1.05B
Pretax Income	1.32B
Net Income	1.18B
EBITDA	1.10B
EBIT	1.05B
Earnings Per Share (EPS)	18.67

Balance Sheet

The company has 2.54 billion in cash and 105.64 million in debt, giving a net cash position of 2.43 billion.

Cash & Cash Equivalents	2.54B
Total Debt	105.64M
Net Cash	2.43B
Net Cash Per Share	n/a
Equity (Book Value)	4.28B
Book Value Per Share	69.49
Working Capital	2.77B

Cash Flow

In the last 12 months, operating cash flow was 1.02 billion and capital expenditures -30.04 million, giving a free cash flow of 988.27 million.

Operating Cash Flow	1.02B
Capital Expenditures	-30.04M
Free Cash Flow	988.27M
FCF Per Share	n/a

Margins

Gross margin is 94.36%, with operating and profit margins of 36.87% and 41.17%.

Gross Margin	94.36%
Operating Margin	36.87%
Pretax Margin	46.28%
Profit Margin	41.17%
EBITDA Margin	38.30%
EBIT Margin	36.87%
FCF Margin	34.54%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.12%
Shareholder Yield	3.12%
Earnings Yield	7.92%
FCF Yield	6.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 9.17 and a Piotroski F-Score of 5.

Altman Z-Score	9.17
Piotroski F-Score	5